peoplePerson
Solange Peters
Solange Peters is a lung cancer trialist and past ESMO President who led CheckMate 743 in mesothelioma.
Solange Peters heads medical oncology at CHUV Lausanne, led CheckMate 743 (nivolumab plus ipilimumab in mesothelioma), and served as ESMO President in 2020-2021.
Role
Head of Medical Oncology, Lausanne University Hospital (CHUV); ESMO President 2020-2021
Institution
Specialisms
Thoracic oncologyImmunotherapyMesothelioma
Profiles
| Title | Journal | Year |
|---|---|---|
| First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743) | Lancet | 2021 |
Pages like this
not linked directly; found by shared links- PairingHistology → first-line choice in mesothelioma
Shares CheckMate 743, Ipilimumab, Mesothelioma, Nivolumab.
- PersonPilar Garrido
Shares European Society for Medical Oncology (ESMO), Non-small-cell lung cancer.
- TrialBEAT-meso (ETOP 13-18)
- TermEpithelioid vs sarcomatoid (biphasic) mesothelioma
Shares CheckMate 743, Mesothelioma.
- PersonPatrick M. Forde
Shares Mesothelioma, Nivolumab, Non-small-cell lung cancer.
- PersonJulie R. Brahmer
Shares Mesothelioma, Nivolumab, Non-small-cell lung cancer.
- TrialCOSMIC-313
Shares Ipilimumab, Nivolumab.
- TrialCheckMate 648
Shares Ipilimumab, Nivolumab.